Syndax Pharmaceuticals, Inc. (SNDX)

NASDAQ: SNDX · IEX Real-Time Price · USD
20.47
+0.30 (1.49%)
Jun 2, 2023, 4:00 PM EDT - Market closed
1.49%
Market Cap 1.41B
Revenue (ttm) n/a
Net Income (ttm) -153.30M
Shares Out 68.82M
EPS (ttm) -2.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,129,234
Open 20.25
Previous Close 20.17
Day's Range 19.99 - 20.56
52-Week Range 14.69 - 29.86
Beta 1.11
Analysts Strong Buy
Price Target 34.17 (+66.93%)
Earnings Date May 8, 2023

About SNDX

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 3, 2016
Employees 107
Stock Exchange NASDAQ
Ticker Symbol SNDX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for SNDX stock is "Strong Buy." The 12-month stock price forecast is $34.17, which is an increase of 66.93% from the latest price.

Price Target
$34.17
(66.93% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WALTHAM, Mass. , June 2, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today annou...

19 hours ago - PRNewsWire

Syndax Announces Participation at Two Upcoming Investor Conferences

WALTHAM, Mass. , May 24, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today annou...

1 week ago - PRNewsWire

Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

– Topline data from the pivotal AGAVE-201 trial of axatilimab in cGVHD on track for mid-2023 – – Topline data from the pivotal AUGMENT-101 trial of revumenib in KMT2Ar acute leukemia on track for the ...

3 weeks ago - PRNewsWire
}

Syndax to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 8, 2023

WALTHAM, Mass. , May 1, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announ...

1 month ago - PRNewsWire

Syndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and Development

- Neil Gallagher, M.D., Ph.D. brings to Syndax over 20 years of experience as a leading  oncology drug developer  - WALTHAM, Mass.

2 months ago - PRNewsWire

Syndax Pharmaceuticals Announces Two Publications in Nature of Data from the Phase 1 Portion of AUGMENT-101 in Acute Leukemia Patients

WALTHAM, Mass. , March 15, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced that data from the Phase 1 portion of the ongoing Phase 1/2 AUGMENT-101 trial of revumenib i...

2 months ago - PRNewsWire

Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update

– Topline data from AUGMENT-101 KMT2Ar patients expected in the third quarter of 2023 – –Topline data from the pivotal AGAVE-201 trial on track for mid-2023 – – Two U.S. registrational filings expecte...

3 months ago - PRNewsWire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

NEW YORK , Feb. 27, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim...

3 months ago - PRNewsWire
}

Syndax to Announce Fourth Quarter and Year-end 2022 Financial Results and Host Conference Call and Webcast on February 28, 2023

WALTHAM, Mass. , Feb. 21, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today anno...

3 months ago - PRNewsWire

Syndax Announces Participation at Upcoming Investor Conferences

WALTHAM, Mass. , Feb. 14, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today anno...

3 months ago - PRNewsWire

Syndax Announces Presentation at 41st Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass. , Jan. 4, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today annou...

5 months ago - PRNewsWire

Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

WALTHAM, Mass. , Dec. 14, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeli...

6 months ago - PRNewsWire

Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting

- 30% CR/CRh rate in efficacy evaluable population; 27% CR/CRh rate observed in both mNPM1 and KMT2Ar (MLLr) R/R acute leukemia patients treated at RP2D - -  9 of 12 patients who underwent stem cell t...

6 months ago - PRNewsWire
}

Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

WALTHAM, Mass. , Dec. 8, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipelin...

6 months ago - PRNewsWire

Syndax Announces Pricing of $150 Million Public Offering of Common Stock

WALTHAM, Mass. , Dec. 6, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipelin...

6 months ago - PRNewsWire

Syndax Announces Proposed $150 million Public Offering of Common Stock

WALTHAM, Mass. , Dec. 6, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipelin...

6 months ago - PRNewsWire

Syndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia

-- Revumenib is the first and only investigational treatment for R/R KMT2Ar acute leukemia to receive Breakthrough Therapy Designation -- -- Designation is based on Phase 1 data from the AUGMENT-101 t...

6 months ago - PRNewsWire

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

– Treatment with axatilimab resulted in an overall response rate (ORR) of 67% across all patients; and an ORR of 82% in patients dosed at 1 mg/kg every 2 weeks in the Phase 2 portion of the trial – – ...

Other symbols: INCY
6 months ago - PRNewsWire

Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer

WALTHAM, Mass. , Dec. 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today annou...

6 months ago - PRNewsWire

Syndax Announces Participation at Evercore ISI Annual HealthCONx Conference

WALTHAM, Mass. , Nov. 21, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today anno...

6 months ago - PRNewsWire

Syndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update

– Updated positive data from Phase 1 portion of AUGMENT-101 trial demonstrates CR/CRh rate of 30% and a median durability of response of 9.1 months – – Enrollment complete in pivotal Phase 2 AGAVE-201...

7 months ago - PRNewsWire

Syndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias

- 30% CR/CRh rate and 53% ORR in R/R acute leukemia patients with NPM1 or MLLr (KMT2Ar) mutations; no discontinuations due to treatment-related adverse events - -  Median duration of CR/CRh response o...

7 months ago - PRNewsWire

Syndax to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022

WALTHAM, Mass. , Oct. 27, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today anno...

7 months ago - PRNewsWire

Syndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update

– On track to report topline data from revumenib and axatilimab pivotal programs starting in 1H23 – – Updated data from Phase 1 portion of AUGMENT-101 trial expected in 4Q22 – – Company to host confer...

10 months ago - PRNewsWire

Syndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022

WALTHAM, Mass. , Aug. 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today annou...

10 months ago - PRNewsWire